Contraception
Volume 75, Issue 1 , Pages 16-22 , January 2007

Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin® 24 Fe)

This work was presented in abstract form in two publications [Abstract P-53 (Fertil Steril 2005;84:S169–S170) and Abstract P-56 (Fertil Steril 2005;84:S171)] at the 61st Annual Meeting of the American Society for Reproductive Medicine, Montreal, Quebec, Canada.

  • Steven T. Nakajima

      Affiliations

    • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Women's Health, University of Louisville, Louisville, KY 40202, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 502 629 2441; fax: +1 502 629 2444.
    • ,
  • David F. Archer

      Affiliations

    • CONRAD Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    • ,
  • Herman Ellman

      Affiliations

    • Warner Chilcott Inc., Clinical Development, Rockaway, NJ 07866, USA

Received 15 May 2006 ,Revised 1 July 2006 ,Accepted 2 August 2006.

References 

  1. Petitti DB. Combination estrogen–progestin oral contraceptives. N Engl J Med. 2003;349:1443–1550
  2. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
  3. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59:357–362
  4. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol. 2001;185:S4–S12
  5. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception. 1999;60:321–329
  6. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Düsterberg B. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel. Contraception. 2001;64:201–207
  7. Maier WE, Herman JR. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001;34:53–61
  8. Dickey RP. Benefits of OCs to reproductive health. In: Managing contraceptive pill patients. 11th ed. Dallas (TX): Essential Medical Informations Systems, Inc.; 2002;p. 10–15
  9. Archer DF, Maheux R, DelConte A, O'Brien FB The North American Levonorgestrel Study Group (NALSG). Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®). Am J Obstet Gynecol. 1999;181(Suppl):S39–S44
  10. Rowan JP. “Estrophasic” dosing: a new concept in oral contraceptive therapy. Am J Obstet Gynecol. 1999;180:S302–S306
  11. Archer DF, Maheux R, DelConte A, O'Brien FB The North American Levonorgestrel Study Group (NALSG). A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg. Contraception. 1997;55:139–144
  12. Boerrigter PJ, Ellman H, Dolker M. International clinical experience with a new low-dose, monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg. Clin Ther. 1999;21:118–127
  13. LaGuardia KD, Shangold G, Fisher A, Friedman A, Kafrissen M The Norgestimate Study Group. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception. 2003;67:431–437
  14. Sulak P, Lippman J, Siu C, Massaro J, Godwin A. Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: cycle control, lipid effects, and user satisfaction. Contraception. 1999;59:161–166
  15. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–582

PII: S0010-7824(06)00317-9

doi: 10.1016/j.contraception.2006.08.004

Contraception
Volume 75, Issue 1 , Pages 16-22 , January 2007

Article Tools

* Image Usage & Resolution